[go: up one dir, main page]

AR129991A1 - Anticuerpos que se unen a la pad4 humana y usos de los mismos - Google Patents

Anticuerpos que se unen a la pad4 humana y usos de los mismos

Info

Publication number
AR129991A1
AR129991A1 ARP230101916A ARP230101916A AR129991A1 AR 129991 A1 AR129991 A1 AR 129991A1 AR P230101916 A ARP230101916 A AR P230101916A AR P230101916 A ARP230101916 A AR P230101916A AR 129991 A1 AR129991 A1 AR 129991A1
Authority
AR
Argentina
Prior art keywords
antibody
antibodies
nucleic acids
isolated
pad4
Prior art date
Application number
ARP230101916A
Other languages
English (en)
Inventor
lin hui Su
Ekaterina DEYANOVA
Burce Ergel Gurbuzbalaban
Mariana Nacht
Samantha Elaine Pace
Yun Wang
Qing Xiao
Ramakrishna Chandran
Shailesh Dudhgaonkar
Michael Louis Doyle
Michael Gilman
Richard Huang
Akbar Nayeem
Alok Sharma
Qihong Zhao
Kofi Mensah
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR129991A1 publication Critical patent/AR129991A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physiology (AREA)

Abstract

La presente solicitud se refiere a determinados anticuerpos anti-PAD4 (peptidil arginina deiminasa 4), ácidos nucleicos que codifican los anticuerpos, vectores y células huésped que comprenden los ácidos nucleicos, y métodos para fabricar y utilizar los anticuerpos. Reivindicación 1: Un anticuerpo aislado que se une específicamente a la proteína arginina deiminasa 4 (PAD4), en el que el anticuerpo comprende una región variable de cadena pesada (VH) que comprende una región determinante de la complementariedad de cadena pesada 1 (HCDR1) que comprende la secuencia de aminoácidos de SEQ ID Nº 62 y una HCDR3 que comprende la secuencia de aminoácidos de SEQ ID Nº 6; y una región variable de cadena ligera (VL) que comprende una región determinante de la complementariedad de cadena ligera 1 (LCDR1) que comprende la secuencia de aminoácidos de SEQ ID Nº 7. Reivindicación 46: Una composición farmacéutica que comprende un anticuerpo de cualquiera de las reivindicaciones 1 - 45 y un vehículo farmacéuticamente aceptable. Reivindicación 47: Un ácido nucleico aislado o un conjunto de dos o más ácidos nucleicos que codifican el anticuerpo de cualquiera de las reivindicaciones 1 - 45. Reivindicación 48: Un vector aislado que comprende uno o más ácidos nucleicos que codifican la cadena pesada y la cadena ligera del anticuerpo de cualquiera de las reivindicaciones 1 - 45. Reivindicación 49: Una célula huésped aislada que comprende el ácido nucleico de la reivindicación 47 o el vector de la reivindicación 48. Reivindicación 50: Un método para producir un anticuerpo que se une específicamente a PAD4 que comprende cultivar la célula huésped de la reivindicación 49 en condiciones adecuadas para la expresión del anticuerpo.
ARP230101916A 2022-07-22 2023-07-21 Anticuerpos que se unen a la pad4 humana y usos de los mismos AR129991A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263369184P 2022-07-22 2022-07-22
US202263397698P 2022-08-12 2022-08-12

Publications (1)

Publication Number Publication Date
AR129991A1 true AR129991A1 (es) 2024-10-23

Family

ID=87696151

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101916A AR129991A1 (es) 2022-07-22 2023-07-21 Anticuerpos que se unen a la pad4 humana y usos de los mismos

Country Status (16)

Country Link
US (1) US20240228664A9 (es)
EP (1) EP4558529A1 (es)
JP (1) JP2025523961A (es)
KR (1) KR20250040994A (es)
CN (2) CN119604537A (es)
AR (1) AR129991A1 (es)
AU (1) AU2023312054A1 (es)
CA (1) CA3261121A1 (es)
CL (1) CL2025000197A1 (es)
CO (1) CO2025000674A2 (es)
IL (1) IL318084A (es)
MA (1) MA71560A (es)
MX (1) MX2025000833A (es)
PE (1) PE20251075A1 (es)
TW (1) TW202423992A (es)
WO (1) WO2024020579A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP2857516B1 (en) 2000-04-11 2017-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
ES2562177T3 (es) 2002-09-27 2016-03-02 Xencor Inc. Variantes de Fc optimizadas y métodos para su generación
EP1562972B1 (en) 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
BRPI0410745A (pt) 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CN101979650B (zh) 2003-10-22 2015-09-16 凯克研究生院 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
BRPI0506771A (pt) 2004-01-12 2007-05-22 Applied Molecular Evolution anticorpo, e, composição farmacêutica
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
PT3221346T (pt) 2014-11-21 2020-10-23 Bristol Myers Squibb Co Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
US11447569B2 (en) * 2015-03-06 2022-09-20 Public University Corporation Yokohama City University Anti-PAD4 antibody
EA201891121A1 (ru) 2015-11-19 2018-12-28 Бристол-Майерс Сквибб Компани Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
WO2019131769A1 (ja) * 2017-12-26 2019-07-04 公立大学法人名古屋市立大学 新規抗ｐａｄ４抗体

Also Published As

Publication number Publication date
US20240228664A9 (en) 2024-07-11
WO2024020579A1 (en) 2024-01-25
TW202423992A (zh) 2024-06-16
US20240132622A1 (en) 2024-04-25
JP2025523961A (ja) 2025-07-25
EP4558529A1 (en) 2025-05-28
CA3261121A1 (en) 2024-01-25
AU2023312054A1 (en) 2025-01-23
CL2025000197A1 (es) 2025-04-04
IL318084A (en) 2025-02-01
MA71560A (fr) 2025-05-30
CN119604537A (zh) 2025-03-11
MX2025000833A (es) 2025-03-07
CN120865421A (zh) 2025-10-31
KR20250040994A (ko) 2025-03-25
PE20251075A1 (es) 2025-04-10
CO2025000674A2 (es) 2025-02-13

Similar Documents

Publication Publication Date Title
AR129991A1 (es) Anticuerpos que se unen a la pad4 humana y usos de los mismos
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
BR112022021397A2 (pt) Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma
AR123083A1 (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
HRP20220088T1 (hr) Dvojno-specifično fixaxfx antitijelo sa zajedničkim lakim lancem
AR123997A1 (es) ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
AR110755A1 (es) Anticuerpos dirigidos a hueso
PE20240086A1 (es) Anticuerpos anti-cd122 y usos de estos
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
AR127629A1 (es) Moléculas de anticuerpo y conjugados
AR123935A1 (es) COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g
AR129935A1 (es) Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
CL2024003622A1 (es) Proteína de unión a antígeno tigit; método de producción; composición farmacéutica; y su uso.
AR128688A1 (es) Anticuerpos anti-cd39 y uso de los mismos
AR124067A2 (es) Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
AR125488A1 (es) Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
AR123728A1 (es) Anticuerpos cd1a y su uso
AR125074A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
AR131528A1 (es) Anticuerpos anti-b7h3 y métodos de uso
AR127270A1 (es) Formulación de anticuerpos anti-cd47
AR132064A1 (es) Anticuerpos anti-cldn6 y métodos de uso